Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at H C Wainwright Healthcare Conference Transcript

Sep 09, 2019 / 04:50PM GMT
Release Date Price: $19.7 (-3.71%)
Douglas Dylan Tsao
H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst

We're ready to go. So welcome, everybody. I'm Doug Tsao. I cover biopharmaceuticals at H.C.W. We're pleased to have a sort of fireside chat or analyst discussion with Coherus, who is represented by Denny Lanfear, CEO of the company. Owning that, I think, for coming up on 4 years of knowing Denny, and it's been really impressive and gratifying to see the progress that he's made. I think when I first met him, they had just completed some of the clinical work on UDENYCA, which is their pegfilgrastim biosimilar, which is now launched and trending incredibly well on the market. And I think I've been noting to people, it's been, by far, the most successful biosimilar launch to date in the U.S. market.

Questions & Answers

Douglas Dylan Tsao
H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst

So with that, Denny, maybe provide a little bit of an update in terms of UDENYCA's commercialization. Where you are today? Where

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot